Literature DB >> 24916463

Extraction of chronically implanted cardiovascular electronic device leads.

Jeffrey Brinker1.   

Abstract

OPINION STATEMENT: Cardiovascular implantable electronic devices (CIED) are a remarkable success story. These systems are widely used to prevent symptomatic bradycardia, treat malignant tachyarrhythmia, and to restore a more physiologic contraction to a failing left ventricle. Implantation of a CIED usually involves a lifelong commitment to this therapy, which, unfortunately, is not free from complication requiring removal and/or replacement of all or part of the system. The major obstacle to removal of a CIED is the fibrous attachments that develop between a lead and co-existent leads, veins, and the heart. This process increases over time such that, by one year, removal by traction alone may be problematic and, if aggressive, result in complication. Physicians, surgeons, and engineers have refined techniques of percutaneous lead extraction and developed tools, which have facilitated the process, increased success, and lowered the incidence of complication. Extraction may be performed for a variety of indications some of which are unanimously agreed upon while others remain controversial. Proponents of a broadened application of extraction have proffered the concept of 'lead management,' which includes the removal of all leads that are not clinically relevant to the patient. The benefit of this approach would be to limit the risk of future complication, such as venous occlusion or thromboembolism, and to obviate the increase in difficulty of extraction (due to longer implant duration) that might accompany removal should that be required in the future. Intuitively appealing as this approach might be, there is little evidence supporting it, and the extraordinarily large number of patients currently implanted with recalled ICD leads is indicative of the potential impact this practice may have. This review will discuss extraction, its indications, and outcomes.

Entities:  

Year:  2014        PMID: 24916463     DOI: 10.1007/s11936-014-0325-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  33 in total

1.  Percutaneous extraction of stented device leads.

Authors:  Bryan Baranowski; Oussama Wazni; Roy Chung; David O Martin; John Rickard; Christine Tanaka-Esposito; Mohammed Bassiouny; Bruce L Wilkoff
Journal:  Heart Rhythm       Date:  2011-12-17       Impact factor: 6.343

2.  Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections.

Authors:  Jean-François Sarrazin; François Philippon; Michel Tessier; Jean Guimond; Franck Molin; Jean Champagne; Isabelle Nault; Louis Blier; Maxime Nadeau; Lyne Charbonneau; Mikaël Trottier; Gilles O'Hara
Journal:  J Am Coll Cardiol       Date:  2012-05-01       Impact factor: 24.094

3.  Lead implant duration does not always predict ease of extraction: extraction sheath may be required at < 1 year.

Authors:  Melanie Maytin; Laurence M Epstein; Roy M John
Journal:  Pacing Clin Electrophysiol       Date:  2011-10-20       Impact factor: 1.976

4.  Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA).

Authors:  Bruce L Wilkoff; Charles J Love; Charles L Byrd; Maria Grazia Bongiorni; Roger G Carrillo; George H Crossley; Laurence M Epstein; Richard A Friedman; Charles E H Kennergren; Przemyslaw Mitkowski; Raymond H M Schaerf; Oussama M Wazni
Journal:  Heart Rhythm       Date:  2009-05-22       Impact factor: 6.343

5.  The current practice and perception of cardiac implantable electronic device transvenous lead extraction in the UK.

Authors:  Manav Sohal; Steven E Williams; Aruna Arujuna; Zhong Chen; Julian Bostock; Jaswinder S Gill; Christopher Aldo Rinaldi
Journal:  Europace       Date:  2012-11-23       Impact factor: 5.214

6.  16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008.

Authors:  Arnold J Greenspon; Jasmine D Patel; Edmund Lau; Jorge A Ochoa; Daniel R Frisch; Reginald T Ho; Behzad B Pavri; Steven M Kurtz
Journal:  J Am Coll Cardiol       Date:  2011-08-30       Impact factor: 24.094

7.  Conservative management of infected pacemaker and implantable defibrillator sites with a closed antimicrobial irrigation system.

Authors:  J Alberto Lopez
Journal:  Europace       Date:  2012-09-26       Impact factor: 5.214

8.  Lead vegetations in patients with local and systemic cardiac device infections: prevalence, risk factors, and therapeutic effects.

Authors:  Pier Giorgio Golzio; Anna Laura Fanelli; Melissa Vinci; Elisa Pelissero; Mara Morello; Walter Grosso Marra; Fiorenzo Gaita
Journal:  Europace       Date:  2012-09-11       Impact factor: 5.214

9.  Do abandoned leads pose risk to implantable cardioverter-defibrillator patients?

Authors:  Michael Glikson; Mahmoud Suleiman; David M Luria; Marjorie L Martin; David O Hodge; Win-Kuang Shen; David J Bradley; Thomas M Munger; Robert F Rea; David L Hayes; Stephen C Hammill; Paul A Friedman
Journal:  Heart Rhythm       Date:  2008-10-11       Impact factor: 6.343

10.  Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.

Authors:  Larry M Baddour; Andrew E Epstein; Christopher C Erickson; Bradley P Knight; Matthew E Levison; Peter B Lockhart; Frederick A Masoudi; Eric J Okum; Walter R Wilson; Lee B Beerman; Ann F Bolger; N A Mark Estes; Michael Gewitz; Jane W Newburger; Eleanor B Schron; Kathryn A Taubert
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.